

Miguel Unda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8545673/publications.pdf>

Version: 2024-02-01

43
papers

2,290
citations

377584

21
h-index

299063

42
g-index

45
all docs

45
docs citations

45
times ranked

3894
citing authors

#	ARTICLE	IF	CITATIONS
1	PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer. <i>Oncogenesis</i> , 2022, 11, 10.	2.1	6
2	Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 667.	1.7	27
3	Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours. <i>Diagnostics</i> , 2021, 11, 272.	1.3	7
4	1H NMR-Based Urine Metabolomics Reveals Signs of Enhanced Carbon and Nitrogen Recycling in Prostate Cancer. <i>Journal of Proteome Research</i> , 2020, 19, 2419-2428.	1.8	21
5	The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer. <i>Cancers</i> , 2020, 12, 513.	1.7	14
6	Seguridad de nivolumab en pacientes con carcinoma de células renales metastásico: experiencia española en urología en la práctica clínica real. <i>Actas Urológicas Españolas</i> , 2019, 43, 364-370.	0.3	3
7	PPAR γ Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. <i>Cancer Research</i> , 2018, 78, 399-409.	0.4	20
8	Revisión de la evidencia sobre el manejo de medicamentos y productos peligrosos en los servicios de Urología. Documento de consenso entre la Asociación Española de Urología y la Sociedad Española de Farmacia Hospitalaria. <i>Actas Urológicas Españolas</i> , 2018, 42, 375-380.	0.3	0
9	Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer. <i>Cell Death and Disease</i> , 2018, 9, 1041.	2.7	14
10	Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1470442.	5.5	103
11	Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. <i>Cell</i> , 2018, 174, 1559-1570.e22.	13.5	183
12	Cáncer de próstata resistente a la castración. Recomendaciones de consenso de la Asociación Española de Urología. <i>Actas Urológicas Españolas</i> , 2017, 41, 141-145.	0.3	6
13	Diagnóstico y tratamiento del cáncer de próstata clínicamente localizado. Adherencia a las guías clínicas en un estudio poblacional nacional "GESCAP". <i>Actas Urológicas Españolas</i> , 2017, 41, 359-367.	0.3	12
14	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	13.7	142
15	Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. <i>PLoS ONE</i> , 2017, 12, e0181711.	1.1	32
16	Comparative miRNA Analysis of Urine Extracellular Vesicles Isolated through Five Different Methods. <i>Cancers</i> , 2016, 8, 112.	1.7	41
17	Vesicle-MaNiA: extracellular vesicles in liquid biopsy and cancer. <i>Current Opinion in Pharmacology</i> , 2016, 29, 47-53.	1.7	55
18	Different EV enrichment methods suitable for clinical settings yield different subpopulations of urinary extracellular vesicles from human samples. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 29497.	5.5	112

#	ARTICLE	IF	CITATIONS
19	Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study. <i>International Urology and Nephrology</i> , 2016, 48, 645-656.	0.6	53
20	Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 127-136.	2.0	17
21	Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer. <i>Oncotarget</i> , 2016, 7, 6835-6846.	0.8	55
22	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. <i>Methods</i> , 2015, 77-78, 25-30.	1.9	16
23	Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. <i>European Urology</i> , 2015, 68, 256-262.	0.9	63
24	Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guérin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non-muscle-invasive Bladder Cancer in Intermediate- and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial. <i>European Urology</i> , 2015, 67, 508-516.	0.9	54
25	Influencia del número real de instilaciones de Bacilo de Calmette-Guérin aplicadas en el pronóstico de los tumores vesicales no músculo-infiltrantes. <i>Actas Urológicas Españolas</i> , 2014, 38, 280-284.	0.3	3
26	Factores que predicen el desarrollo de metástasis óseas por cáncer de próstata: recomendaciones de seguimiento y opciones terapéuticas. <i>Actas Urológicas Españolas</i> , 2014, 38, 263-269.	0.3	5
27	A phase II dose-ranging study of mirabegron in patients with overactive bladder. <i>International Urogynecology Journal</i> , 2013, 24, 1447-1458.	0.7	121
28	Tratamiento del cáncer de próstata y cáncer renal con fármacos orales (abiraterona y Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Td). <i>Españolas</i> , 2013, 37, 321-323.	0.3	3
29	Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. <i>British Journal of Cancer</i> , 2013, 109, 121-130.	2.9	19
30	Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. <i>British Journal of Cancer</i> , 2013, 108, 2565-2572.	2.9	31
31	The impact of peptidase activity on clear cell renal cell carcinoma survival. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, F1584-F1591.	1.3	37
32	Is the Bench Getting Closer to the Bedside in the War on Cancer? A Quick Look at Prostate Cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 53.	1.5	5
33	1740 RETROSPECTIVE STUDY OF DIFFERENT OPTIONS IN THE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER T1G3: MAINTENANCE BCG IS HERE TO STAY. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
34	Prostate cancer in Spain: from guidelines to clinical practice. <i>BJU International</i> , 2011, 108, 61-66.	1.3	16
35	The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables. <i>European Urology</i> , 2011, 60, 423-430.	0.9	148
36	Treatment of Renal Tumors by Percutaneous Ultrasound-Guided Radiofrequency Ablation Using a Multitined Electrode: Effectiveness and Complications. <i>European Urology</i> , 2010, 57, 459-465.	0.9	39

#	ARTICLE	IF	CITATIONS
37	Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. <i>Journal of Urology</i> , 2009, 182, 2195-2203.	0.2	480
38	Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials. <i>European Urology</i> , 2008, 53, 992-1002.	0.9	220
39	MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR T1G3 OR T1G3 AND/OR CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMISED CUETO GROUP STUDY. <i>European Urology Supplements</i> , 2008, 7, 298.	0.1	4
40	594 FACTORS AFFECTING TUMOR RECURRENCE AND PROGRESSION OF NON-MUSCLE INVASIVE BLADDER CANCER (TA, T1, TIS) TREATED WITH BACILLUS CALMETTE-GUÉRIN. MULTIVARIATE ANALYSIS OF DATA FROM FOUR RANDOMIZED CUETO TRIALS. <i>European Urology Supplements</i> , 2007, 6, 171.	0.1	0
41	Influence of sociodemographic and health status variables on the american urological association symptom scores in patients with lower urinary tract symptoms. <i>Urology</i> , 2001, 57, 71-77.	0.5	31
42	Effect of Mode of Administration on I–PSS Scores in a Large BPH Patient Population. <i>European Urology</i> , 2001, 40, 451-457.	0.9	10
43	Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): Multicenter trial comparing bacille calmette-guérin and interferon-alpha. <i>Urology</i> , 1997, 50, 529-535.	0.5	55